Gene therapy injection aims to restore sight in rare blindness
NCT ID NCT06952842
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. The therapy is injected into the eye and uses a harmless virus to deliver a gene-editing tool. The trial includes 18 adults and will check safety and whether it improves vision over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZVS203e (a gene therapy using a harmless virus to deliver a gene-editing tool into the eye)
What this could lead to
If successful, this could slow or partially reverse vision loss in people with a specific genetic form of retinitis pigmentosa.
What could go wrong
This is an early-phase trial with only 18 participants, so results may not apply to everyone. Gene therapies can cause inflammation or other side effects, and vision improvement may be limited or temporary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100191, China